Answers are grounded in this paper and cite their sources.
Analysis distinguishes ctnnb1 mutant HCCs and suggests a non-invasive imaging approach for patient stratification.
Motivation: Aberrant activation of the CTNNB1/Wnt pathway is a common molecular alteration in Hepatocellular Carcinoma (HCC) that has been found to impact patients' response to therapy; however, there is a deficiency of non-invasive biomarkers for stratifying HCC patients based on CTNNB1 mutational status. Goal(s): We sought to identify a novel non-invasive molecular imaging biomarker of CTNNB1/Wnt pathway mutation in HCCs. Approach: We assessed metabolic flux in clinically relevant HCC patient-derived xenografts in vivo using Hyperpolarized 1-13C Pyruvate Magnetic Resonance Spectroscopy. Results: We observed an 86% higher and 14% lower Hyperpolarized 1-13C Pyruvate conversion to Alanine and Lactate respectively in CTNNB1mutant HCCs compared to non-mutants. Impact: CTNNB1 mutant and non-mutant HCCs can be distinguished non-invasively by assessing Hyperpolarized-1-13C-Pyruvate flux to Alanine and Lactate. Our findings present a promising precision imaging strategy for patient stratification, with the potential to enhance treatment outcomes in HCC and other cancers.
No takes yet. Share an insight, caveat, or question.
Adebesin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: